|
Clinicopathological characteristics of breast cancer patients underwent radiotherapy with different genotypes in relation to the risk of recurrence
|
Y. Ma   , Y. Pan , B. Zhang , Y. Zhang , W. Fan |
| Department of Pathology, Department of Basic Medicine, Shijiazhuang Medical College, Shijiazhuang, 050599, China , panyunye2020@126.com |
|
|
Abstract: (118 Views) |
Background: This study aims to analyze the clinicopathological characteristics of breast cancer (BC) patients with different genotypes who underwent radiotherapy. The goal is to explore the relationship between these characteristics and the risk of recurrence, providing valuable insights for clinical adjuvant therapy. Materials and Methods: A retrospective analysis was conducted on pathological data of 256 BC patients who underwent surgical resection and radiotherapy. Data included age structure, tumor diameter and grading, estrogen receptor (ER) and progesterone receptor (PR) indicators, human epidermal growth factor receptor 2 (HER2), and the cell proliferation antigen marker (Ki-67). Multifactorial analysis was employed to assess correlations. Results: The distribution of BC patients in the low, medium-high, and high-risk groups was 70.9%, 23.2%, and 5.6%, respectively. Multifactorial analysis revealed that PR, Ki-67 expression, and histological grading were independent factors influencing the RS score, with corresponding P values less than 0.05. They were positively correlated (P < 0.001) with Ki-67 expression levels and tumor tissue grading, and negatively correlated with hormonal indicators. The short-term probability of survival for patients with the four staged BC in the low-risk group was 82.34%, 76.12%, 62.13%, and 60.23%, and 23.69%, respectively. Triple negative breast cancer (TNBC) patients and those with Luminal B BC exhibited a higher risk of metastasis (P < 0.05). Conclusion: The pathological characteristics of BC patients with different genotypes showed significant differences. TNBC patients and those with Luminal B BC should be particularly vigilant about their risk of recurrence and metastasis, and strengthen prognostic considerations. |
|
| Keywords: Gene expression level, breast cancer, estrogen receptor, progesterone receptor, recurrence risk score. |
|
|
Full-Text [PDF 709 kb]
(29 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| References |
1. 1. Waks AG and Winer EP (2019) Breast Cancer Treatment: A Review. Jama, 321(3): 288-300. [ DOI:10.1001/jama.2018.19323] [ PMID] 2. Trayes KP and Cokenakes SE (2021) Breast cancer treatment. Am Fam Physician, 104(2): 171-8. 3. Du Z, Wang L, Zhou Y, Wan H, Liang F, Lyu Q (2018) Association of CYP19A1 gene rs7176005 single nucleotide polymorphism with breast cancer risk and clinicopathologic features of tumor. Zhonghua Yu Fang Yi Xue Za Zhi (Chinese Journal of Preventive Medicine), 52(8): 827-832. 4. Tsang JY, Gary MT (2020) Molecular classification of breast cancer. Adv Anat Pathol, 27(1): 27-35. [ DOI:10.1097/PAP.0000000000000232] [ PMID] 5. Al-Eitan LN, Rababa'h DM, Alghamdi MA, Khasawneh RH (2019) Correlation between candidate single nucleotide variants and several clinicopathological risk factors related to breast cancer in Jordanian women: a genotype-phenotype study. J Cancer, 10(19): 4647. [ DOI:10.7150/jca.33857] [ PMID] [ ] 6. Ivashkiv LB (2018) IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat Rev Immunol, 18(9): 545-58. [ DOI:10.1038/s41577-018-0029-z] [ PMID] [ ] 7. Gluz O, Nitz UA, Christgen M, Kates RE, Shak S, Clemens M, et al. (2016) West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. J Clin Oncol, 34(20): 2341-2349. [ DOI:10.1200/JCO.2015.63.5383] [ PMID] 8. Crager M, Wijayawardana SR, Gruver AM, Blacklock A, Russell C, Baehner FL, et al. (2022) Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2−, node-positive early breast cancer. BREAST Cancer Res, 24(1): 1-7. [ DOI:10.1186/s13058-022-01571-7] [ PMID] [ ] 9. Sahebjam S, Aloyz R, Pilavdzic D, Brisson M, Ferrario C, Bouganim N, et al. (2011) Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score. Brit J Cancer 8.0, 105(9): 1342-5. [ DOI:10.1038/bjc.2011.402] [ PMID] [ ] 10. Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, et al. (2022) Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol, 40(16): 1816-1837. [ DOI:10.1200/JCO.22.00069] [ PMID] 11. Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, et al. (2022) Breast cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Ne, 20(6): 691-722. 12. Wang JW, Wei XL, Dou XW, Huang WH, Du CW, Zhang GJ (2018) The association between Notch4 expression, and clinicopathological characteristics and clinical outcomes in patients with breast cancer. Oncol Lett, 15(6): 8749-8755. [ DOI:10.3892/ol.2018.8442] [ PMID] [ ] 13. Kim JO, Schaid DJ, Vachon CM, et al. (2021) Impact of Personalized Genetic Breast Cancer Risk Estimation with Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.Cancer Prev Res, 14(2): canprevres.0154. [ DOI:10.1158/1940-6207.CAPR-20-0154] [ PMID] 14. Sessler DI, Pei L, Huang Y, Fleischmann E, Marhofer P, Kurz A, et al. (2019) Recurrence of breast cancer after regional or general anaesthesia: a randomised controlled trial. The Lancet, 394(10211): 1807-1815. [ DOI:10.1016/S0140-6736(19)32313-X] 15. Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, et al. (2018) Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor-positive breast cancer treated with 5 years of endocrine therapy: CTS5. J Clin Oncol, 36(19): 1941. [ DOI:10.1200/JCO.2017.76.4258] [ PMID] [ ] 16. Jayaseelan VP, Ramesh A, Arumugam P (2021) Breast cancer and DDT: putative interactions, associated gene alterations, and molecular pathways. Environ Sci Pollut R, 28(21): 27162-27173. [ DOI:10.1007/s11356-021-12489-6] [ PMID] 17. Rugo HS and Huppert L (2021) Answers are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.Clin Cancer Res, 27(12): clincanres.0353. [ DOI:10.1158/1078-0432.CCR-21-0353] [ PMID] 18. Zhao S, Ma D, Xiao Y, Jiang YZ, Shao ZM (2018) Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. Eur J Surg Oncol, 44(4): 420-428. [ DOI:10.1016/j.ejso.2017.11.027] [ PMID] 19. Li Y, Yang D, Yin X, Zhang X, Huang J, Wu Y, et al. (2020) Clinicopathological characteristics and breast cancer-specific survival of patients with single hormone receptor-positive breast cancer. Jama Netw Open, 3(1): e1918160. [ DOI:10.1001/jamanetworkopen.2019.18160] [ PMID] [ ] 20. Heil J, Kuerer H, Pfob A, Rauch G, Sinn H, Golatta M, et al. (2020) Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges. Ann Oncol, 31(1): 61-71. [ DOI:10.1016/j.annonc.2019.10.012] [ PMID] 21. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio I, et al. (2019) Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 30(8): 1194-220. [ DOI:10.1093/annonc/mdz173] [ PMID] 22. Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kümmel S, et al. (2022) Event-free survival with pembrolizumab in early triple-negative breast cancer. N Engl J Med, 386(6): 556-67. [ DOI:10.1056/NEJMoa2112651] [ PMID] 23. Abubakar M, Figueroa J, Ali HR, Blows F, Lissowska J, Caldas C, et al. (2019) Combined quantitative measures of ER, PR, HER2, and KI67 provide more prognostic information than categorical combinations in luminal breast cancer. Mod Pathol, 32(9): 1244-1256. [ DOI:10.1038/s41379-019-0270-4] [ PMID] [ ] 24. Wang K, Li HL, Xiong YF, Shi Y, Li ZY, Li J, et al. (2019) Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study. Cancer Med, 8(2): 686-700. [ DOI:10.1002/cam4.1880] [ PMID] [ ] 25. Hu H, HU X, Li D, Cai J (2023) Cryptococcosis mimicking pulmonary metastasis during treatment with tamoxifen for breast cancer after surgery: A case report. Int J Radiat Res, 21(4): 845-848. [ DOI:10.61186/ijrr.21.4.845] 26. Rakici SY, Eren M (2023) Intensity-modulated radiation therapy (IMRT) with couch rotation in right unilateral breast cancer. Int J Radiat Res, 21(2): 203-210 27. Sporikova Z, Koudelakova V, Trojanec R, Hajduch M (2018) Genetic markers in triple-negative breast cancer. Clin Breast Cancer, 18(5): e841-e850. [ DOI:10.1016/j.clbc.2018.07.023] [ PMID] 28. Fragomeni SM, Sciallis A, Jeruss JS (2018) Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin, 27(1): 95-120. [ DOI:10.1016/j.soc.2017.08.005] [ PMID] [ ] 29. Wang MX, Ren JT, Tang LY, Ren ZF (2018) Molecular features in young vs elderly breast cancer patients and the impacts on survival disparities by age at diagnosis. Cancer Medus, 7(7): 3269-3277. [ DOI:10.1002/cam4.1544] [ PMID] [ ] 30. Wei G, Rosa M, Chang M, et al. (2021) Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.J Clin Oncol, 39(15_suppl): 10526-10526. [ DOI:10.1200/JCO.2021.39.15_suppl.10526] 31. Fu F, Zhang D, Hu L, et al. (2022) Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women. Cancer Biol Med, 19(2): 253-262. 32. Bahaddin MM (2020) A comparative study between Ki67 positive versus Ki67 negative females with breast cancer: Cross sectional study. Ann Med Surg, 60: 232-235. [ DOI:10.1016/j.amsu.2020.10.049] [ PMID] [ ] 33. Celepli P, Karabulut S, Bigat R, et al. (2022) CD47 expression and tumor-associated immune cells in breast cancer and their correlation with molecular subtypes and prognostic factors. Pathol Res Pract, 238: 154107. [ DOI:10.1016/j.prp.2022.154107] [ PMID] 34. Ishii T and Nakamura Y (2020) Precision Medicine for Advanced Solid Malignancies Based on Circulating Tumor DNA Analysis.Gan to kagaku ryoho. Cancer & chemotherapy, 47(12): 1645-1652. 35. Fawzy MS, Toraih EA, Alelwani W, et al. (2020) The prognostic value of microRNA-biogenesis genes Argonaute 1 and 2 variants in breast cancer patients. Am J Transl Res, 12(5): 1994-2006.
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
|
Ma Y, Pan Y, Zhang B, Zhang Y, Fan W. Clinicopathological characteristics of breast cancer patients underwent radiotherapy with different genotypes in relation to the risk of recurrence. Int J Radiat Res 2024; 22 (4) :1043-1050 URL: http://ijrr.com/article-1-5803-en.html
|
